Entity
  • AeproMED innovation corp.,Ltd.

    Created in 2022


  • To investigate (B)
    Some signals may appear as inconsistent with a regular activity
  • Social networks

    88
  • Activities

  • Technologies

  • Entity types

  • Location

    Shengyi 5th Rd, Zhubei City, Hsinchu County, Taiwan 302

    Zhubei City

    Taiwan

  • Employees

    Scale: 11-50

    Estimated: 2

  • Engaged catalyst

    1
    0 0
  • Added in Motherbase

    11 months, 2 weeks ago
Description
  • Value proposition

    Elevate Your Well-being with the AirHyper Platform
    **************************************************************
    AeproMED Pioneering a New Era in Inhalation Development

    AirHyper Platform is the ultimate solution for unlocking the power of inhalation therapy. It offers a multitude of advantages that can transform your wellness journey. Our advanced inhalation therapy platform offers a gentle yet potent approach, making it accessible to a wide range of individuals, even pre-clinical animals.

    🌟 Advantages of AirHyper Inhalation Therapy:
    1. Seamless Transition from Animal to Human Models: AirHyper's inhalation therapy serves as a crucial bridge between animal models and human trials, facilitating smoother transitions in pre-clinical research.

    2. Precision Targeted Delivery: AirHyper ensures precise delivery of medications to the intended sites, optimizing treatment efficacy.

    3. High-Dose Precision: Our platform enables high-dose delivery, ensuring patients receive the right amount of medication for effective treatment.

    4. Real-Time Drug Monitoring: AirHyper's data tracking capabilities allow for real-time monitoring of drug usage, enhancing treatment management and patient care.



Catalyst interactions
Catalyst Type Tweets Articles
La French Tech Taiwan
La French Tech Taiwan
French Tech, Technology, Information and Internet (Auto)
La French Tech Taiwan
French Tech, Technology, Information and Internet (Auto)
Other

27 Feb 2023


Social network dynamics
Similar entities
BETA
Loading...
Loading...